These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19153941)

  • 1. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
    Baptista T; Rangel N; El Fakih Y; Uzcátegui E; Galeazzi T; Beaulieu S; Araujo de Baptista E
    Pharmacopsychiatry; 2009 Jan; 42(1):14-9. PubMed ID: 19153941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
    Baptista T; Rangel N; Fernández V; Carrizo E; El Fakih Y; Uzcátegui E; Galeazzi T; Gutiérrez MA; Servigna M; Dávila A; Uzcátegui M; Serrano A; Connell L; Beaulieu S; de Baptista EA
    Schizophr Res; 2007 Jul; 93(1-3):99-108. PubMed ID: 17490862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
    Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
    Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
    Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
    Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
    Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
    J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
    Baptista T; Sandia I; Lacruz A; Rangel N; de Mendoza S; Beaulieu S; Contreras Q; Galeazzi T; Vargas D
    Int Clin Psychopharmacol; 2007 Mar; 22(2):69-76. PubMed ID: 17293706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
    Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
    Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
    Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
    Poyurovsky M; Tal V; Maayan R; Gil-Ad I; Fuchs C; Weizman A
    Eur Neuropsychopharmacol; 2004 Aug; 14(4):332-6. PubMed ID: 15163444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.
    Paslakis G; Deuschle M; Thome J; Rüsse S; Kopf D
    Pharmacopsychiatry; 2012 May; 45(3):96-9. PubMed ID: 22174030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
    Yi Z; Fan X; Wang J; Liu D; Freudenreich O; Goff D; Henderson DC
    Psychiatry Res; 2012 Dec; 200(2-3):79-82. PubMed ID: 22727707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
    Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
    Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.
    Fadai F; Mousavi B; Ashtari Z; Ali beigi N; Farhang S; Hashempour S; Shahhamzei N; Bathaie SZ
    Pharmacopsychiatry; 2014 Jul; 47(4-5):156-61. PubMed ID: 24955550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.
    Moghimi Sarani E; Memari E; Anushiravani A; Mowla A
    J Clin Psychopharmacol; 2020; 40(5):487-490. PubMed ID: 32701903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
    Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
    J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.
    Fan X; Copeland P; Nawras S; Harrington A; Freudenreich O; Goff DC; Henderson DC
    Psychopharmacology (Berl); 2019 Jun; 236(6):1949-1957. PubMed ID: 30747254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.